Company Snapshot
- Ticker
- ABBV
- Name
- ABBV
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 398965800000.000000
- Volume
- 3,985,095
- Avg Volume (3M)
- 5,469,415
ABBV
ABBV
Last update recent
225.15
+2.16
(+0.97%)
Market Cap
398965800000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 59644000000.000000
- EPS
- 1.33
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 2.88%
- Net Income
- 2394000000.000000
- Net Margin
- 4.01%
- Payout Ratio
- 480.28%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 166.65
- Forward P/E
- None
- P/S
- 6.69
- P/B
- -153.51
- Beta
- None
- Debt / Equity
- -26.45
- Current Ratio
- 0.72
- Return on Equity
- -0.92%
- Return on Assets
- 0.02%
Technicals & Returns
- Distance vs 200 DMA
- 11.07%
- 200 DMA
- 202.71
- Distance vs 50 DMA
- -1.12%
- 50 DMA
- 227.69
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chro Read more
- Name
- ABBV
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Robert A. Michael
- Employees
- 50,000
- IPO Date
- 2013-01-02
- Phone
- 847 932 7900
- Address
- None
- Website
- https://www.abbvie.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-10-15 • $1.55
Latest News
Curated headlines from premium sources.
Rep. Julie Johnson Sells Off Shares of AbbVie Inc. (NYSE:ABBV)
Representative Julie Johnson (D-Texas) recently sold shares of AbbVie Inc. (NYSE: ABBV). In a filing disclosed on December 11th, the Representative disclosed t…
Caldwell Trust Co Takes Position in AbbVie Inc. $ABBV
Caldwell Trust Co bought a new stake in shares of AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to the company in its most recent disclosure…
My Top 3 Healthcare Stocks to Buy in 2026
With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly rapidly and e…
5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine
Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividen…
Why Ditching Schwab U.S. Dividend Equity ETF In the AI Era Is a Mistake
The rapid rise of artificial intelligence (AI) has transformed the stock market in recent years, powering massive gains in technology giants and growth-oriente…
Ameriprise Financial Inc. Sells 3,127,890 Shares of AbbVie Inc. $ABBV
Ameriprise Financial Inc. decreased its stake in AbbVie Inc. (NYSE: ABBV) by 25.2% during the undefined quarter, according to the company in its most recent fi…